Gan & Lee Pharmaceuticals. Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals.

603087

Kedudukan dalam Saham #3014
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Harga Saham
$10.03
Modal Pasaran
$5.99B
Perubahan (1 hari)
-3.71%
Perubahan (1 tahun)
2.30%
Negara
CN
Perdagangan Gan & Lee Pharmaceuticals. (603087)

Kategori

Healthcare
Nisbah P/S bagi Gan & Lee Pharmaceuticals. (603087)
Nisbah P/S pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Gan & Lee Pharmaceuticals., nisbah P/S semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/S syarikat ialah 0.
Sejarah nisbah P/S untuk Gan & Lee Pharmaceuticals. dari 2013 hingga 2026
Nisbah P/S pada akhir setiap tahun
Tahun Nisbah P/S Ubah
2025 9.98 16.64%
2024 8.56 -25.20%
2023 11.44 7.09%
2022 10.68 -2.29%
2021 10.94 -50.49%
2020 22.08 74.82%
2019 12.63 -8.28%
2018 13.77 -0.87%
2017 13.89 -25.30%
2016 18.60 -31.05%
2015 26.97 -23.67%
2014 35.34 -20.02%
2013 44.18 0.00%
Nisbah P/S untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/S Perbezaan Nisbah P/S Negara
13.45 -
US
2.32 -
FR
- -
JP
2.47 -
US
- -
CH